LIDDS — Lidds AB Share News
0.000.00%
Last trade - 00:00- SEK3.36m
- SEK1.62m
Brief: Lidds Announces Positive Topline Results From Phase I Study
Brief: LIDDS Patent Covering The Nanozolid® Production Process Granted In China
Brief: Lidds July-Sept Net Sales at Sek 4.0 million
Brief: Lidds AB Says Nanozolid Formulated Docetaxel Is Safe And Tolerable Showing Signs Of Clinical Efficacy
Brief: Lidds Patent Covering Nanozolid Production Process Granted In Russia And Australia
Brief: Lidds Q2 Loss Before Tax Widens To SEK 9.8 Mln
Brief: Lidds Appoints Jenni Björnulfson New CFO
Brief: Lidds AB Intends To Carry Out A Directed Share Issue Of Approximately MSEK 45
Brief: Lidds Q1 Loss Rises To SEK 10.8 Mln
Brief: Lidds: Prostate Cancer Study To Be Initiated At Uppsala University Hospital With Nanozolid Technology
Brief: Lidds Updates On Clinical Program For Liproca Depot
Brief: Lidds Nanozolid Technology Approved In All Countries Concerned
Brief: Lidds Enters R&D Agreement With Potential Exclusive, Global Product License Option
Brief: LIDDS And Pharmidea Sign Manufacturing Agreement
Brief: Lidds Says Study With Liproca Depot Meet Endpoints
Brief: Lidds To Apply For Listing On Nasdaq Stockholm Main Market
Brief: Lidds AB - Nmpa Has Extended Requirements To A Full Registration Dossier For Conditional Market Approval
Brief: Lidds Announces The Appointment Of Nina Herne As CEO
Brief: Lidds Q3 Loss Before And After Tax Narrows To SEK 6.6 Mln